Distribution of TYMS, MTHFR, p53 and MDR1 gene polymorphisms in patients with breast cancer treated with neoadjuvant chemotherapy

被引:28
作者
Alberto Henriquez-Hernandez, Luis [1 ,3 ]
Murias-Rosales, Adolfo [2 ,3 ]
Gonzalez-Hernandez, Ana [3 ,4 ]
Cabrera de Leon, Antonio [3 ,4 ]
Diaz-Chico, Nicolas [3 ,5 ]
Fernandez-Perez, Leandro [1 ,3 ]
机构
[1] Univ Las Palmas Gran Canaria, Dept Clin Sci, Las Palmas Gran Canaria 35016, Spain
[2] Hosp Univ Insular Gran Canaria, Med Oncol Serv, Las Palmas Gran Canaria 35016, Spain
[3] ICIC, Madrid, Spain
[4] Hosp La Candelaria, Hosp Univ La Candelaria, Res Unit, Santa Cruz De Tenerife 38010, Spain
[5] Univ Las Palmas Gran Canaria, Physiol Biochem & Mol Biol Dept, Las Palmas Gran Canaria 35016, Spain
关键词
Breast cancer; Neoadjuvant chemotherapy; Toxicity; Adverse reaction; Polymorphism; MTHFR; p53; ACUTE LYMPHOBLASTIC-LEUKEMIA; METHYLENETETRAHYDROFOLATE REDUCTASE C677T; THYMIDYLATE SYNTHASE; OVARIAN-CANCER; TOXICITY; PHARMACOGENOMICS; THERAPY; RESISTANCE; VARIANTS; RISK;
D O I
10.1016/j.canep.2010.06.013
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose To investigate the role of TSER (TYMS), C677T (MTHFR), Arg72Pro (p53) and C3435T (MDR1) gene polymorphisms in breast cancer patients treated with 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy. Results Observed allelic frequencies were: TSER, (2) 0.54 and (3) 0.46; MTHFR C677T, (C) 0.59 and (T) 0.41; p53 Arg72Pro, (Arg) 0.73 and (Pro) 0.27; MDR1 C3435T, (C) 0.52 and (T) 0.48. MTHFR allele T and p53 allele Pro were strongly associated with toxicity due to chemotherapy (odds ratio, 7.1 (95% confidence interval, 1.4-36.1; p = 0.018) and 7.0 (95% confidence interval, 1.2-40.5; p = 0.029), respectively). Conclusion We introduced new data related to the contribution of p53 codon 72 to toxicity due to 5-fluorouracil and cyclophosphamide-based neoadjuvant chemotherapy in patients with breast cancer. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:634 / 638
页数:5
相关论文
共 45 条
[41]   Influence of MTHFR and RFC1 Polymorphisms on Toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma [J].
Shimasaki, Noriko ;
Mori, Tetyuya ;
Torii, Chiharu ;
Sato, Reiko ;
Shimada, Hiroyuki ;
Tanigatvara, Yusuke ;
Kosaki, Kenjiro ;
Takahashi, Takao .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2008, 30 (05) :347-352
[42]   MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF) [J].
Toffoli, G ;
Veronesi, A ;
Boiocchi, M ;
Crivellari, D .
ANNALS OF ONCOLOGY, 2000, 11 (03) :373-374
[43]   p53 codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer [J].
Xu, Y ;
Yao, LH ;
Ouyang, T ;
Li, JF ;
Wang, TF ;
Fan, ZQ ;
Lin, BY ;
Lu, YY ;
Xie, YT .
CLINICAL CANCER RESEARCH, 2005, 11 (20) :7328-7333
[44]  
Zárate R, 2007, CURR DRUG METAB, V8, P481
[45]  
Zubor P, 2007, ONCOL REP, V18, P211